THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic ...
Lexicon (LXRX) announced an update to the previous submission of additional clinical data to the FDA from ongoing third-party funded, investigator-initiated studies supporting the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback